Pfizer's Monthly Berobenatide Could Transform Obesity Treatment

Pfizer revealed data on its new obesity drug berobenatide, following its acquisition of Metsera. The monthly dose showed similar side effects to Novo Nordisk's Wegovy. Analysts focus on its side-effect profile for commercial viability. Results demonstrate a 12.3% weight loss in the VESPER-3 trial.

Pfizer has announced promising data regarding its experimental obesity drug, berobenatide, which was acquired through its $10 billion purchase of Metsera. The company reported a weight loss of up to 12.3% in patients without diabetes during its VESPER-3 trial. This monthly-dose drug aims to rival Novo Nordisk's weekly Wegovy injections.

The drug, characterized by a similar side-effect profile to its competitor Wegovy, hopes to offer less frequent, more patient-friendly dosing options. Analysts are keeping a close watch on its side effects to gauge its market potential, particularly focusing on gastrointestinal issues, which were notably concentrated around initial doses.

Pfizer executives highlighted that a longer half-life creates a smoother profile compared to weekly doses. While an increase in adverse events was observed when transitioning from weekly to monthly doses, Pfizer plans to adjust dosages gradually in future trials. Investor interest remains high, especially in the aftermath of Pfizer's earlier challenges with its weight-loss drugs.